Download as pdf or txt
Download as pdf or txt
You are on page 1of 1

Constipation Management Algorithm

Assessment (A1) BM bowel movement


Hyperlinks indicate
• Normal bowel habit WBC white blood cell count
additional information • Current bowel performance (A3) Plt platelet count
available in guideline o Stool frequency
sections above: o Stool consistency
A = Assessment o Ease of evacuation Manage according to
M = Management FPON guideline,
Medical Management
Yes of Malignant Bowel
Obstructed Obstruction
bowel?

No
PREVENTION No Yes TREATMENT
needed needed (M2)
Constipation?

1. Rectum empty; OR
No Yes 2. Contraindications to rectal
Irritable bowel
intervention:
syndrome?
• neutropenia (WBC <0.5) OR
• thrombocytopenia (Plt <20)

Osmotic Laxative Sennosides-­based Protocol (M4+5)


No Rectal Measures (M3)
(M4+5) success • Escalating doses until satisfactory BM
• Manual disimpaction
• Lactulose or sorbitol • Maximum senna dose 36 mg tid
(if indicated)
• Polyethylene glycol • Add rectal measures at any time
• Glycerin supp
• Escalating doses until if indicated and no
• Bisacodyl supp
satisfactory BM contraindications (M3)
• Microlax enema
• Fleet enema*
No • Warm water enema
success
• Oil enema
followed by
Assess cause
Sennosides-­based Protocol
Hypomobility
(e.g., ascites, Opioid-­induced (M9)
autonomic neuropathy,
abdominal cancer)
Consider switching to less
constipating opioid (e.g., fentanyl)

Consider prokinetic agent


(e.g., domperidone, metoclopramide)
Add or switch to
osmotic laxative

Add or switch to
osmotic laxative Consider methylnaltrexone (or naloxegol)
No success

Palliative Care Consult *Contraindicated in patients with renal failure.

BCGuidelines.ca: Palliative Care for the Patient with Incurable Cancer or Advanced Disease Part 2: Pain and Symptom Management – Constipation (2017)

You might also like